Brokerages Expect Castle Biosciences, Inc. (NASDAQ:CSTL) Will Post Quarterly Sales of $28.60 Million

Wall Street analysts expect that Castle Biosciences, Inc. (NASDAQ:CSTLGet Rating) will report $28.60 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Castle Biosciences’ earnings, with the lowest sales estimate coming in at $28.59 million and the highest estimate coming in at $28.60 million. Castle Biosciences reported sales of $22.76 million during the same quarter last year, which indicates a positive year-over-year growth rate of 25.7%. The business is scheduled to issue its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Castle Biosciences will report full year sales of $116.80 million for the current fiscal year. For the next financial year, analysts forecast that the company will post sales of $154.38 million, with estimates ranging from $153.75 million to $155.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Castle Biosciences.

Castle Biosciences (NASDAQ:CSTLGet Rating) last released its quarterly earnings data on Monday, May 9th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.26). Castle Biosciences had a negative net margin of 33.26% and a negative return on equity of 7.49%. During the same quarter in the prior year, the company earned ($0.17) EPS.

Several research firms have recently commented on CSTL. Lake Street Capital lowered their price objective on shares of Castle Biosciences from $94.00 to $63.00 in a research note on Tuesday, March 1st. Canaccord Genuity Group cut their price objective on Castle Biosciences from $80.00 to $65.00 in a report on Tuesday. Robert W. Baird cut their price objective on Castle Biosciences from $50.00 to $44.00 in a report on Tuesday. Canaccord Genuity Group cut their price objective on Castle Biosciences from $94.00 to $80.00 and set a “buy” rating on the stock in a report on Tuesday, April 5th. Finally, Zacks Investment Research lowered Castle Biosciences from a “hold” rating to a “sell” rating in a report on Thursday, April 28th. One analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $62.57.

In other Castle Biosciences news, Director Daniel Bradbury sold 8,852 shares of the stock in a transaction that occurred on Tuesday, February 22nd. The stock was sold at an average price of $39.02, for a total transaction of $345,405.04. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders sold 26,556 shares of company stock worth $1,084,813 in the last 90 days. Company insiders own 15.40% of the company’s stock.

A number of hedge funds have recently modified their holdings of CSTL. US Bancorp DE lifted its position in shares of Castle Biosciences by 28.9% in the first quarter. US Bancorp DE now owns 16,468 shares of the company’s stock valued at $739,000 after acquiring an additional 3,694 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Castle Biosciences by 16.8% in the first quarter. Bank of New York Mellon Corp now owns 101,886 shares of the company’s stock valued at $4,570,000 after purchasing an additional 14,658 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Castle Biosciences by 3.2% in the first quarter. JPMorgan Chase & Co. now owns 24,324 shares of the company’s stock valued at $1,091,000 after purchasing an additional 754 shares during the last quarter. Advisors Capital Management LLC increased its holdings in shares of Castle Biosciences by 3.6% in the first quarter. Advisors Capital Management LLC now owns 17,630 shares of the company’s stock valued at $791,000 after purchasing an additional 617 shares during the last quarter. Finally, Essex Investment Management Co. LLC increased its holdings in shares of Castle Biosciences by 27.5% in the first quarter. Essex Investment Management Co. LLC now owns 117,245 shares of the company’s stock valued at $5,260,000 after purchasing an additional 25,310 shares during the last quarter. Institutional investors own 84.29% of the company’s stock.

Shares of CSTL opened at $18.10 on Thursday. The company has a market cap of $461.30 million, a price-to-earnings ratio of -14.60 and a beta of 1.11. Castle Biosciences has a twelve month low of $18.08 and a twelve month high of $78.92. The company has a 50 day moving average of $33.56 and a two-hundred day moving average of $40.38.

About Castle Biosciences (Get Rating)

Castle Biosciences, Inc, a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma.

Recommended Stories

Get a free copy of the Zacks research report on Castle Biosciences (CSTL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Castle Biosciences (NASDAQ:CSTL)

Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.